Are you currently facing difficulty in achieving high-purity BsAb expression, long development cycles, and overcoming the IgG mispairing problem? Our IgG-Fv BsAb Generation Service helps you accelerate lead generation and obtain manufacturable bispecific drug candidates through advanced IgG-scaffold engineering and structure-guided interface redesign.
Contact our team to get an inquiry now!
Bispecific antibodies (BsAbs) represent the next frontier in therapy, moving beyond monospecific monoclonal antibodies (mAbs) to enable the simultaneous engagement of two distinct antigens for superior efficacy through synergistic mechanisms, such as T-cell redirection or receptor co-ligation. This capability is vital for overriding resistance pathways in complex diseases. The IgG-Fv is an advanced, Fc-containing format engineered to retain the favorable pharmacokinetics (PK) of native IgG. This leverages the FcRn-mediated recycling pathway, ensuring a long serum half-life and reduced dosing frequency, which is crucial for systemic treatments. Critically, this format achieves multi-valency (2+1)-a bivalent bind to the primary target and a monovalent bind to the secondary target.
Fig.1 Diagram of IgG(L,H)-Fv BsAb.
IgG(L,H)-Fv BsAbs, a category of bispecific antibodies featuring enhanced properties and considerable therapeutic promise, are generated through the fusion of VH and VL domains to the carboxyl terminus of two separate heavy chains. This configuration results in an intact immunoglobulin molecule that incorporates an extra Fv segment at its C-terminal end. The engineered Fv at the C-terminus exhibits single binding specificity, whereas the two identical Fv regions located at the N-terminus, characteristic of a standard full-length IgG, confer bivalent antigen engagement. The association between the C-terminal VH and VL domains may additionally promote heavy chain hetero-specificity, allowing the IgG(L,H)-Fv to simultaneously interact with distinct target antigens using different valencies.
Creative Biolabs is the undisputed pioneer in generating robust, manufacturable BsAb formats, solving the classic IgG mispairing problem that often stalls lead generation.
A: IgG-Fv retains the full Fc region, providing a significantly longer serum half-life via FcRn recycling, which allows for less frequent dosing and greater systemic efficacy compared to the short half-life of Fc-less fragments. This format is ideal for long-term therapeutic intervention.
A: We use a two-pronged approach: controlled Genetic Fusion of the Fv fragment and Structure-Guided Interface Redesign (mutations in CH1-CL and CH3-CH3) to enforce correct chain pairing, resulting in purities often exceeding 80% from a single expression run.
A: Absolutely. The 2+1 valency is ideal for T-cell engagers, typically using the bivalent IgG arms to bind the tumor cell and the monovalent Fv arm to engage CD3 on the T-cell, providing stability and targeted cytotoxic redirection.
A: Our service is designed to harmonize the constant regions. We apply conserved, engineered mutations that are portable across IgG subtypes, ensuring compatibility and stable assembly while addressing the specific TPP requirements (e.g., using an IgG4-like scaffold to eliminate Fc effector function if needed).
A: We provide detailed reports from multiple complementary analytical tools, including SEC (for size and aggregation), DSF (for thermal stability), and dual-antigen binding assays (like FIDA) to confirm the high quality and functionality of the final candidate. Contact us to review sample data packages.
Experience the Creative Biolabs Advantage - Get a Quote Today
Welcome! For price inquiries, we will get back to you as soon as possible.
INQUIRY
SERVICES
PRODUCTS
PLATFORMS
